Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Trabecular bone loss may contribute to axial spondyloarthritis progression

Publish date:: September 16, 2020

Key clinical point: Trabecular bone loss could predict syndesmophyte formation and disease progression in axial spondyloarthritis.

Major finding: Trabecular bone loss is associated with more syndesmophyte formation than no trabecular bone loss.

Study details: A prospective, observational cohort study in 245 patients with axial spondyloarthritis.

Disclosures: The study received no funding, and the authors said they had no conflicts of interest to declare.

Citation:

Jung J-Y et al. Semin Arthritis Rheum. 2020;50(5):827-33.

This Week's Must Reads

Osteoporosis prevalence in PsA similar to general population,

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases,

Weight loss may be paramount lifestyle change in preventing gout,

Gut microbiome influences response to methotrexate in new-onset RA patients,

Early treatment of RA with DMARDs promotes sustained remission,

Must Reads in Ankylosing spondylitis

Etanercept may not help some with suspected nonradiographic axial spondyloarthritis,

Novel study explores link between primary immunodeficiencies, rheumatic diseases,

Lower TNF inhibitor efficacy observed in women with nonradiographic axSpA,

Shingrix effective in older adults with preexisting immune-mediated disorders,

Trabecular bone loss may contribute to axial spondyloarthritis progression,